STI-6129

STI-6129 is an antibody-drug conjugate developed by Zhejiang ACEA Pharmaceutical. Its target is CD38 (the sponsor names CD38). The sponsor states: Anti-CD38 human antibody covalently bound to a duostatin tubulin inhibitor payload. ClinicalTrials.gov describes the intervention as: Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT05565807, plans to enrol 84 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.